Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bio-Thera Approved to Market Humira Biosimilar in China

publication date: Jan 10, 2020

Bio-Thera Solutions, a Guangzhou biopharma, reported its Humira® (adalimumab) biosimilar has been approved for China use. Qletli®, the first Bio-Thera product approved for commercialization and the second biosimilar approved by China's NMPA, is indicated to treat three autoimmune diseases: rheumatoid arthritis, ankylosing spondylitis and plaque psoriasis. In early 2019, Henlius' biosimilar to Genentech's Rituxan (rituximab) was approved in China to treat non-Hodgkin lymphoma. Bio-Thera is developing a portfolio of biosimilar and novel biologic molecules for immuno-oncology and autoimmune disease. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital